Adverse effects from antidepressant treatment: Randomised controlled trial of 601 depressed individuals

Psychopharmacology

Volumn 231, Issue 15, 2014, Pages 2921-2931

  Crawford, Andrew A ^a   Lewis, Sarah ^a   Nutt, David ^b   Peters, Tim J ^a   Cowen, Philip ^c   O'Donovan, Michael C ^d   Wiles, Nicola ^a   Lewis, Glyn ^e  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse effects; Antidepressants; Citalopram; Depression; NARI; Noradrenaline reuptake inhibitor; Reboxetine; Selective serotonin reuptake inhibitor; SSRI

Indexed keywords

CITALOPRAM; REBOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; MORPHOLINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; HYPERHIDROSIS; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SLEEP DISORDER; TACHYCARDIA; TORONTO SIDE EFFECTS SCALE; TREATMENT DURATION; TREMOR; XEROSTOMIA; CHEMICALLY INDUCED; DEPRESSIVE DISORDER; TIME FACTOR; TREATMENT REFUSAL;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER; DIZZINESS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MORPHOLINES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT REFUSAL;

EID: 84904443071     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3467-8     Document Type: Article

References (52)

1. Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36
2. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, Matthews K, McAllister-Williams RH, Peveler RC, Scott J, Tylee A, P. British Assoc (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343-396 (Pubitemid 351989984)
3. Andersson KE (2011) Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 63:811-859
4. Bailey JE, Potokar J, Coupland N, Nutt DJ (1995) The 5-HT3 antagonist ondansetron reduces gastrointestinal side-effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9:137-141
5. Beck AT, Erbaugh J, Ward CH, Mock J, Mendelsohn M (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
6. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW(2002) Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36:578-584 (Pubitemid 34270268)
7. Carpenter J, Kenward M (2013) Guidelines for handling missing data in Social Science Research. London School of Hygiene and Tropical Medicine. http://missingdata.lshtm.ac.uk/downloads/guidelines.pdf. Accessed 23 Aug 2013
8. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758
9. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE (2003) Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 18:151-156 (Pubitemid 36571059)
10. Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196-201 (Pubitemid 28071427)
11. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P (2001) Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 62:30-33 (Pubitemid 32937583)
12. Donoghue J, Tylee A, Wildgust H (1996) Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. Br Med J 313:861-862 (Pubitemid 26335213)
13. Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR (1999) Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 13:136-143 (Pubitemid 29276823)
14. Evans M, Kessler D, Lewis G, Peters TJ, Sharp D (2004) Assessing mental health in primary care research using standardized scales: can it be carried out over the telephone? Psychol Med 34:157-162 (Pubitemid 38139450)
15. Eyding D, Lelgemann M, Grouven U, Haerter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737
16. Ferguson JM (2001a) SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3:22
17. Ferguson JM (2001b) The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 62:22-34
18. Frank E, Judge R (2001) Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. J Clin Psychiatry 62:10-15 (Pubitemid 32937580)
19. Goldstein BJ, Goodnick PJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12:S55-S87 (Pubitemid 28556670)
20. Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J (2004) Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 26:1446-1455 (Pubitemid 39582713)
21. Gruenberg AM (2009) Stahl's essential psychopharmacology: neuroscientific basis and practical applications, third edition. Psychol Med 39:520-521
22. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EHF (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23-44 (Pubitemid 38381173)
23. Haug TT, Mykletun A, Dahl AA (2004) The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study. Psychosom Med 66:845-851 (Pubitemid 39552867)
24. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE (2004) Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65:959-965
25. Kessler D, Lewis G, Kaur S, Wiles N, King M, Weich S, Sharp DJ, Araya R, Hollinghurst S, Peters TJ (2009) Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet 374:628-634
26. Krska J, Morecroft CW (2013) Patients' use of information about medicine side effects in relation to experiences of suspected adverse drug reactions: a cross-sectional survey in medical in-patients. Drug Saf 36:673-680
27. Lamb GC, Green SS, Heron J (1994) Can physicians warn patients of potential side-effects without fear of causing those side effects. Arch Intern Med 154:2753-2756 (Pubitemid 24378447)
28. Langworth S, Bodlund O, Agren H (2006) Efficacy and tolerability of reboxetine compared with citalopram - a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 26:121-127 (Pubitemid 43740334)
29. Lewis G (1994) Assessing psychiatric-disorder with a human interviewer or a computer. J Epidemiol Community Health 48:207-210
30. Lewis G, Pelosi AJ, Araya R, Dunn G (1992) Measuring psychiatric-disorder in the community - a standardized assessment for use by lay interviewers. Psychol Med 22:465-486
31. Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D (2011) Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry 198:464
32. Lingam R, Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105:164-172 (Pubitemid 34280688)
33. Masand PS (2003) Tolerability and adherence issues in antidepressant therapy. Clin Ther 25:2289-2304
34. Middleton HC, Nutt DJ, Anastassiades P (1988) Evidence that imipramine-induced postural hypotension may be centrally mediated. Hum Psychopharmacol Clin Exp 3:181-190
35. Moeller HJ (2001) Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 251:13-20
36. Montgomery SA, Bebbington P, Cowen P, Deakin W, Freeling P, Hallstrom C, Katona C, King D, Leonard B (1993) Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 7:19-23
37. Morehouse R, MacQueen G, Kennedy SH (2011) Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord 132:S14-S20
38. NHS (2011) Prescription Cost Analysis England 2010. P. U. NHS Information Centre for Health and Social Care, London
39. Nutt DJ, Glue P (1991) Imipramine in panic disorder. 2. Effects on alpha2-adrenoceptor function. Journal of psychopharmacol (Oxford, England) 5:135-141
40. Schweitzer I, Maguire K, Ng C (2009) Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 43:795-808
41. StataCorp (2011) Stata statistical software. College station. StataCorp LP, TX
42. Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen P, Nutt D, O'Donovan M, Sharp D, Peters T, Lewis G (2008) GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials 9:29
43. Thompson AJ (2013) Recent developments in 5-HT3 receptor pharmacology. Trends Pharmacol Sci 34:100-109
44. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, Team SS (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. A J Psychiatry 163:28-40
45. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, Zobel A, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ (2009a) Adverse reactions to antidepressants. Br J Psychiatry 195:202-210
46. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P (2009b) Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194:252-259
47. Vanderkooy J, Kennedy SH, Bagby RM (2002) Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 47:174-180 (Pubitemid 34464559)
48. Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, Gabbay M, Tarrier N, Addington-Hall J (2000) Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. Br Med J 321:1383-1388
49. Warden D, Trivedi MH, Wisniewski SR, Kurian B, Zisook S, Kornstein SG, Friedman ES, Miyahara S, Leuchter AF, Fava M, Rush AJ (2010) Early adverse events and attrition in selective serotonin reuptake inhibitor treatment a suicide assessment methodology study report. J Clin Psychopharmacol 30:259-266
50. WHO (1992). The ICD-10 classification of mental and behavioural disorders clinical descriptions and diagnostic guidelines
51. Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Lewis G (2012) Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry 200:130-136
52. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655-679